- Home
- VERU vs ADAP Comparison
VERU vs ADAP Comparison
Compare VERU & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- ADAP
- Stock Information
- Founded
- VERU 1971
- ADAP 2008
- Country
- VERU United States
- ADAP United Kingdom
- Employees
- VERU N/A
- ADAP N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- VERU Health Care
- ADAP Health Care
- Exchange
- VERU Nasdaq
- ADAP Nasdaq
- Market Cap
- VERU 85.5M
- ADAP 75.5M
- IPO Year
- VERU 1990
- ADAP 2015
- Fundamental
- Price
- VERU $0.49
- ADAP $0.10
- Analyst Decision
- VERU Strong Buy
- ADAP Hold
- Analyst Count
- VERU 2
- ADAP 6
- Target Price
- VERU $4.00
- ADAP $1.02
- AVG Volume (30 Days)
- VERU 1.4M
- ADAP 9.5M
- Earning Date
- VERU 08-07-2025
- ADAP 08-11-2025
- Dividend Yield
- VERU N/A
- ADAP N/A
- EPS Growth
- VERU N/A
- ADAP N/A
- EPS
- VERU N/A
- ADAP N/A
- Revenue
- VERU $16,886,419.00
- ADAP $179,639,000.00
- Revenue This Year
- VERU N/A
- ADAP N/A
- Revenue Next Year
- VERU N/A
- ADAP $38.72
- P/E Ratio
- VERU N/A
- ADAP N/A
- Revenue Growth
- VERU 134.43
- ADAP 878.53
- 52 Week Low
- VERU $0.45
- ADAP $0.10
- 52 Week High
- VERU $1.42
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- VERU 34.85
- ADAP 27.86
- Support Level
- VERU $0.57
- ADAP $0.10
- Resistance Level
- VERU $0.61
- ADAP $0.36
- Average True Range (ATR)
- VERU 0.04
- ADAP 0.02
- MACD
- VERU -0.01
- ADAP -0.01
- Stochastic Oscillator
- VERU 0.13
- ADAP 2.65
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.